GoodRx
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 2 weeks.
- Recent price momentum is -3.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 1.0% of float.
- Analyst tilt is Sell.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 48.7x | Better than 10% |
| Forward P/E | 27.7x | Better than 21% |
| Price / Sales | 1.5x | Better than 65% |
| P/E vs own 5-yr range | 80th pctl | Better than 26% |
Growth C
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 1.3% | Better than 32% |
| Free cash flow CAGR (3Y) | 0.8% | Better than 39% |
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 92.8% | Better than 97% |
| Operating margin | 11.0% | Better than 54% |
| Net margin | 3.8% | Better than 39% |
| Return on equity | 4.5% | Better than 36% |
| Return on invested capital | 4.6% | Better than 43% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -15.4% | Better than 39% |
| 6-month return | 10.2% | Better than 72% |
| 12-month return (ex latest month) | 33.6% | Better than 72% |
| Distance below 52-week high | 24.9% | Better than 51% |
Financial Health B
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.6x | Better than 68% |
| Debt to assets | 38.7% | Better than 28% |
| Interest coverage | 2.3x | Better than 39% |
| Free cash flow / net income | 308.4% | Better than 86% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 3.02
- Open
- 2.98
- Day range
- 2.91 - 3.09
- Avg price
- 2.97
- Volume
- 2.01M
- Turnover
- 5.97M
- Turnover ratei
- 2.15%
- Volume ratioi
- 1.62
- Amplitudei
- 5.96%
- 52-week rangei
- 1.77 - 3.89
Valuation
- P/Ei
- 32.44
- P/E (TTM)i
- 48.67
- P/Bi
- 1.54
- EPSi
- 0.09
- Book value / shi
- 1.90
- Net profit
- 30.70M
- Net assets
- 647.49M
Share structure
- Market cap
- 996.14M
- Float capi
- 272.92M
- Shares out
- 341.15M
- Float sharesi
- 93.47M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-09-23
24.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.81M net over the window
Short interest
- Shares short
- 3.57M
- % of floati
- 1.05%
- Days to coveri
- 3.00
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of GoodRx (GDRX)?
GoodRx last traded at 2.92. This page shows a periodic quote snapshot. Check the displayed quote time.
What is GoodRx's market cap?
About 996.14M.
What is the P/E ratio of GoodRx?
The trailing twelve-month P/E is 48.67. The Valuation tab shows it against the stock's own five-year range.
Does GoodRx pay a dividend?
GoodRx does not currently pay a regular dividend.
Is GoodRx a buy according to analysts?
The consensus of 1 analysts is a Sell rating, with an average 12-month price target of 2.65, which implies 9.2% downside from the current price. This is not investment advice.
What is GoodRx's StockVane Quant Rating?
The StockVane Momentum strategy currently rates GoodRx a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:50:20 · For reference only, not investment advice and not tailored to your situation.
GoodRx discussion 0 comments